Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells (Q40733541)

23 September 2017

Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells (English)

1 reference

23 September 2017

6

Sylvie Mader

1 reference

23 September 2017

Annie Barsalou

1

1 reference

23 September 2017

Guila Dayan

2

1 reference

23 September 2017

Silvia I Anghel

3

1 reference

23 September 2017

Moulay Alaoui-Jamali

4

1 reference

23 September 2017

Patrick Van de Velde

5

1 reference

23 September 2017

1 April 2002

1 reference

Molecular and Cellular Endocrinology

23 September 2017

1 reference

23 September 2017

190

1 reference

23 September 2017

1-2

1 reference

23 September 2017

65-73

1 reference

Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Rapid activation of MAP kinase by estrogen in the bone cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Molecular determinants of tissue selectivity in estrogen receptor modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa).

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Antiestrogens: mechanisms and actions in target cells

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Estrogen receptor pathways to AP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Tamoxifen to raloxifene and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

The case for clinical trials of tamoxifen for prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Risk of endometrial cancer after tamoxifen treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Breast cancer prevention study aims to overcome drug bias

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta ) at AP-1 sites

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

A simple and sensitive high-throughput assay for steroid agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900011-4

7 January 2021

10.1016/S0303-7207(02)00011-4

Identifiers

DOI

1 reference

23 September 2017

1 reference